Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.

Anouk E.J. Latenstein,T.M. Mackay,Geert-Jan Creemers,Casper H.J. van Eijck,Jan Willem B. de Groot,Nadia Haj Mohammad,Marjolein Y.V. Homs,Hanneke W. M. van Laarhoven,I. Quintus Molenaar,Bert Jan ten Tije,Judith de Vos-Geelen,Marc G. Besselink,Lydia G. M. van der Geest,Johanna W. Wilmink

Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.

2020

Anouk E.J. Latenstein
T.M. Mackay
Geert-Jan Creemers
Casper H.J. van Eijck
Jan Willem B. de Groot
Nadia Haj Mohammad
Marjolein Y.V. Homs
Hanneke W. M. van Laarhoven
I. Quintus Molenaar
Bert Jan ten Tije
Judith de Vos-Geelen
Marc G. Besselink
Lydia G. M. van der Geest
Johanna W. Wilmink

AbstractBackground: Positive results of randomized trials led to the introduction of FOLFIRINOX in 2012 and gemcitabine with nab-paclitaxel in 2015 for patients with metastatic pancreatic ductal ad...

Keywords:

Medicine
pancreatic ductal adenocarcinoma
population based
Oncology
Chemotherapy
Pathology
FOLFIRINOX
Internal medicine
Randomized controlled trial
Gemcitabine
Population
Proportional hazards model
Cancer registry

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations